The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
Open accessAbstract
Key Points: Isatuximab (anti-CD38 monoclonal antibody) given with lenalidomide/ dexamethasone is active in heavily pretreated relapsed/refractory myeloma Overall, the safety profile of this combination is similar to the characteristic safety profiles of the individual agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 5×
“Stage I 0 1 (33) 4 (17) 6 (50) 5 (36) 16 (28)”
InfluentialCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Management and Preparedness for Infusion and Hypersensitivity Reactions
Lenz, H.-J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-601 · Cited by 479
Deckert, J., Wetzel, M.-C., Bartle, L. M., Skaletskaya, A., Goldmacher, V. S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0695 · Cited by 333
Research works printed but not linked: 22
- Rajkumar, 2012, Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?, 354
- Eshaghian, 2012, Multiple myeloma: improved outcomes with new therapeutic approaches, Curr Opin Support Palliat Care, 6, 330, 10.1097/SPC.0b013e3283565c56 · DOI
- Palumbo, 2012, Continuous lenalidomide treatment for newly diagnosed multiple myeloma, N Engl J Med, 366, 1759, 10.1056/NEJMoa1112704 · DOI · Paper page
- Kumar, 2008, Improved survival in multiple myeloma and the impact of novel therapies, Blood, 111, 2516, 10.1182/blood-2007-10-116129 · DOI · Paper page
- San-Miguel, 2016, Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial, Lancet Haematol, 3, e506, 10.1016/S2352-3026(16)30147-8 · DOI
- Siegel, 2016, VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory mulltiple myeloma, Clin Lymphoma Myeloma Leuk, 16, 329, 10.1016/j.clml.2016.02.042 · DOI
- Kumar, 2012, Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study [published correction appears in Leukemia. 2012;26(5):1153], Leukemia, 26, 149, 10.1038/leu.2011.196 · DOI · Paper page
- Lonial, 2016, Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma, Expert Opin Biol Ther, 16, 1291, 10.1080/14712598.2016.1221920 · DOI
- Palumbo, 2016, Daratumumab, bortezomib and dexamethasone for multiple myeloma, N Engl J Med, 375, 754, 10.1056/NEJMoa1606038 · DOI · Paper page
- Roguska, 1994, Humanization of murine monoclonal antibodies through variable domain resurfacing, Proc Natl Acad Sci USA, 91, 969, 10.1073/pnas.91.3.969 · DOI · Paper page
- Martin, 2015, A dose finding phase II trial of isatuximabtuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/refractory multiple myeloma [abstract], Blood, 126, 10.1182/blood.V126.23.509.509 · DOI
- Durie, 2006, International uniform response criteria for multiple myeloma [published correction appears in Leukemia. 2006;21:1134; Leukemia. 2006;20(12):2220], Leukemia, 20, 1467, 10.1038/sj.leu.2404284 · DOI · Paper page
- Xu, 2013, Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1, Cancer Immunol Immunother, 62, 1637, 10.1007/s00262-013-1466-y · DOI
- Mitsiades, 2013, Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma, Crit Rev Oncol Hematol, 88, S5, 10.1016/j.critrevonc.2013.05.014 · DOI
- Chan, 2014, Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy, Clin Exp Immunol, 175, 49, 10.1111/cei.12196 · DOI
- Rajkumar, 2011, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, 117, 4691, 10.1182/blood-2010-10-299487 · DOI · Paper page
- João, 2015, Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center, Ann Hematol, 94, 97, 10.1007/s00277-014-2164-3 · DOI
- Dimopoulos, 2014, Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma, Blood Cancer J, 4, e257, 10.1038/bcj.2014.77 · DOI
- Yang, 2013, Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials, PLoS One, 8, e64354, 10.1371/journal.pone.0064354 · DOI
- San Miguel, 2013, Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial, Lancet Oncol, 14, 1055, 10.1016/S1470-2045(13)70380-2 · DOI · Paper page
- Richardson, 2015, Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study, Lancet Haematol, 2, e516, 10.1016/S2352-3026(15)00197-0 · DOI
- Plesner, 2016, Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma, Blood, 128, 1821, 10.1182/blood-2016-07-726729 · DOI
Cited by
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Attal, M., Richardson, P. G., Rajkumar, S. V., San-Miguel, J., Beksac, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., Dimopoulos, M. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32556-5 · Cited by 645
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Metadata
- Authors
- Martin, T., Baz, R., Benson, D. M., Lendvai, N., Wolf, J., Munster, P., Lesokhin, A. M., Wack, C., Charpentier, E., Campana, F., & Vij, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-06-22
- Volume
- 129
- Issue
- 25
- Pages
- 3294-3303
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2612430336
- Cited by
- 166
- References
- 9
- FWCI
- 18.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2016-09-740787
- The paper
- Martin, T., Baz, R., Benson, D. M., Lendvai, N., Wolf, J., Munster, P., Lesokhin, A. M., Wack, C., Charpentier, E., Campana, F., & Vij, R. (2017). A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. https://doi.org/10.1182/blood-2016-09-740787
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.